Residency · Residency · Radiation Oncology

Esophageal Cancer: Neoadjuvant Chemoradiation (CROSS Protocol)

Overview

Esophageal cancer primarily consists of two histologic types: squamous cell carcinoma (SCC) and adenocarcinoma, each with distinct epidemiologic patterns and treatment considerations. SCC is more prevalent worldwide and is strongly linked to risk factors such as smoking, alcohol consumption, and certain endemic dietary exposures. In contrast, adenocarcinoma incidence is rising in Western countries and is associated with gastroesophageal reflux disease (GERD) and Barrett esophagus. For locally advanced esophageal cancer—defined as clinical stage T2 or higher, or node-positive disease—neoadjuvant chemoradiation (nCRT) followed by surgery has become the standard treatment approach, largely based on the results of the CROSS trial. Definitive chemoradiation without surgery is typically reserved for cervical esophageal cancer, patients who are medically inoperable, or those with SCC where organ preservation is a priority.

Landmark Clinical Trials

CROSS Trial (van Hagen et al., 2012; 10-year update 2015)

The CROSS trial was a pivotal phase III study comparing neoadjuvant chemoradiation plus surgery to surgery alone in patients with resectable esophageal or gastroesophageal junction (GEJ) cancer staged as cT1N1 or cT2-3N0-1. The neoadjuvant chemoradiation regimen consisted of 41.4 Gy delivered in 23 fractions (1.8 Gy per fraction) combined with weekly carboplatin (area under the curve [AUC] 2) and paclitaxel (50 mg/m²) for five weeks. The trial demonstrated a pathologic complete response (pCR) rate of 29% overall, with a notably higher rate in SCC (49%) compared to adenocarcinoma (23%). Median overall survival (OS) was significantly improved in the nCRT plus surgery arm at 48.6 months versus 24.0 months for surgery alone. Five-year OS rates were 47% versus 33%, with a hazard ratio of 0.657 favoring the combined modality. The R0 resection rate was also higher with nCRT (92% vs. 69%), and importantly, the addition of chemoradiation did not increase surgical morbidity or mortality. Benefits were observed across both SCC and adenocarcinoma histologies. This trial established nCRT as the standard of care for resectable esophageal cancer.

FLOT4 (Al-Batran et al., 2019)

The FLOT4 trial was a phase III study comparing perioperative chemotherapy with the FLOT regimen—comprising 5-fluorouracil (5-FU), leucovorin, oxaliplatin, and docetaxel—to the older ECF/ECX regimens in patients with GEJ and gastric adenocarcinoma, including Siewert types I to III tumors. FLOT demonstrated improved median OS (50 months vs. 35 months) and higher pCR rates. This regimen has emerged as a competing standard for GEJ adenocarcinoma, with ongoing debate about the optimal approach between perioperative FLOT chemotherapy and neoadjuvant chemoradiation as per CROSS. The ESOPEC trial, reported in 2024, randomized patients with esophageal and GEJ adenocarcinoma to CROSS versus FLOT and found superior OS with FLOT. The NEO-AEGIS trial, comparing CROSS to perioperative chemotherapy (MAGIC/FLOT), is also reporting results, further informing this evolving landscape.

Definitive Chemoradiation (RTOG 85-01)

The RTOG 85-01 trial was a phase III study comparing radiation therapy alone (64 Gy) to concurrent chemoradiation (50 Gy plus cisplatin and 5-FU) in patients with esophageal cancer. Concurrent chemoradiation was markedly superior, with a 5-year OS of 27% compared to 0% with radiation alone, establishing CRT as the standard non-surgical treatment. The INT 0123 trial (Minsky et al., 2002) later compared standard-dose (50.4 Gy) to high-dose (64.8 Gy) radiation with concurrent CRT and found no benefit to dose escalation beyond 50.4 Gy, with increased toxicity at the higher dose.

SCOPE1 (Crosby et al., 2013)

The SCOPE1 trial was a phase III study evaluating definitive CRT with or without cetuximab for esophageal cancer. The addition of cetuximab resulted in worse outcomes, including higher treatment-related mortality. This trial confirmed that a regimen of 50 Gy in 25 fractions combined with cisplatin and capecitabine remains a standard definitive CRT approach.

Radiation Therapy Technique

Neoadjuvant Setting (CROSS Protocol)

In the neoadjuvant setting, radiation is delivered as 41.4 Gy in 23 fractions of 1.8 Gy each over five weeks. The gross tumor volume (GTV) includes the primary tumor identified by endoscopy, endoscopic ultrasound (EUS), computed tomography (CT), and positron emission tomography (PET-CT), along with involved lymph nodes. The clinical target volume (CTV) expands the GTV by 3 to 4 cm craniocaudally and 1 to 1.5 cm radially, respecting anatomic boundaries such as the vertebral body posteriorly and the pericardium medially. This margin accounts for potential submucosal tumor spread along the esophagus. The planning target volume (PTV) further expands the CTV by 5 to 10 mm to accommodate respiratory motion and setup uncertainties. Four-dimensional CT (4D-CT) is recommended for distal esophageal and GEJ tumors to account for respiratory motion. The CROSS protocol does not include elective nodal irradiation beyond the involved nodal stations.

Definitive Setting

For definitive chemoradiation, the radiation dose is typically 50 to 50.4 Gy delivered in 25 to 28 fractions of 1.8 to 2.0 Gy each. Dose escalation beyond 50.4 Gy is not recommended due to lack of benefit and increased toxicity demonstrated in the INT 0123 trial. Because surgery does not follow definitive CRT, larger CTV margins may be used to cover at-risk nodal stations based on tumor location. For cervical esophageal tumors, the supraclavicular and upper mediastinal nodes are included; for mid-thoracic tumors, subcarinal and para-esophageal nodes are targeted; and for distal or GEJ tumors, the celiac axis and perigastric nodes are encompassed.

Beam Arrangement

Intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) is strongly preferred to minimize radiation dose to the heart and lungs. This is especially important for distal esophageal and GEJ tumors, where cardiac dose parameters such as heart V30 and mean heart dose must be carefully controlled. Three-dimensional conformal radiation therapy (3D-CRT) using anterior-posterior/posterior-anterior (AP/PA) and lateral or oblique fields is feasible but less conformal. Proton therapy offers a potential advantage in reducing cardiac and pulmonary dose for long-segment or distal esophageal tumors, with results from the NRG-GI006 trial comparing proton therapy to IMRT eagerly awaited.

Organs at Risk Constraints

Dose constraints for organs at risk are critical to minimize toxicity. For the lungs, the volume receiving 20 Gy (V20) should be kept at or below 30%, V10 at or below 40%, and the mean lung dose at or below 15 Gy. The heart should be limited to a V30 of 46% or less and a mean dose of 26 Gy or less, with efforts to reduce dose further based on cardiac toxicity data from RTOG 0617. The spinal cord maximum dose should not exceed 45 Gy. For distal and GEJ tumors, the liver mean dose should be kept below 30 Gy, bilateral kidneys should have V20 less than or equal to 33%, and the stomach V45 should be limited to 50%.

Concurrent Chemotherapy

Neoadjuvant (CROSS Regimen)

The CROSS regimen employs weekly intravenous carboplatin at an AUC of 2 and paclitaxel at 50 mg/m² for five weeks concurrently with radiation. This regimen is well tolerated, with low rates of grade 3 to 4 hematologic toxicity, and is simple, convenient, and reproducible.

Definitive CRT Options

Definitive chemoradiation regimens include cisplatin (75 mg/m² on days 1 and 29) combined with continuous infusion 5-FU (1000 mg/m²/day on days 1–4 and 29–32), as used in RTOG 85-01. The carboplatin/paclitaxel regimen from CROSS is also employed in definitive CRT settings. Cisplatin with capecitabine, as in the SCOPE1 trial, and FOLFOX chemotherapy are increasingly used based on data from the PRODIGE5/ACCORD17 trial.

Surgical Considerations

Timing

Surgery is typically scheduled 6 to 8 weeks after completion of neoadjuvant chemoradiation, with the CROSS protocol recommending 4 to 6 weeks. This interval allows adequate recovery from treatment-related toxicity. Some evidence suggests that longer intervals of 8 to 12 weeks may improve pathologic response assessment.

Surgical Approaches

The choice of surgical approach depends on tumor location. The Ivor Lewis esophagectomy, involving right thoracotomy and laparotomy, is commonly used for mid-to-distal esophageal tumors. The McKeown procedure, a three-field esophagectomy with cervical anastomosis, is preferred for proximal tumors. Transhiatal esophagectomy, which avoids thoracotomy, is an option for distal and GEJ tumors. Minimally invasive esophagectomy (MIE) and robotic-assisted approaches are increasingly utilized, offering decreased morbidity while maintaining equivalent oncologic outcomes.

Pathologic Response and Prognosis

Pathologic complete response (pCR), defined as ypT0N0, is the strongest prognostic factor following neoadjuvant chemoradiation and surgery, correlating with over 50% five-year overall survival. Tumor regression grading using the Mandard system (TRG 1 to 5) further stratifies outcomes, with TRG 1 (complete response) and TRG 2 (near-complete response) associated with the best prognosis. SCC demonstrates higher pCR rates than adenocarcinoma after nCRT.

<image>A schematic of the CROSS trial design and results. The top portion shows the randomization schema: eligible patients (cT1N1 or cT2-3N0-1 esophageal/GEJ cancer) randomized to nCRT (41.4 Gy + carboplatin/paclitaxel) followed by surgery versus surgery alone. The bottom portion shows Kaplan-Meier overall survival curves for both arms, with median OS (48.6 vs. 24.0 months), 5-year OS rates (47% vs. 33%), and hazard ratio annotated. pCR rates are displayed separately for SCC (49%) and adenocarcinoma (23%).</image>

<image>An axial CT image at the level of a mid-thoracic esophageal tumor showing target volume delineation for neoadjuvant radiation (CROSS protocol). The GTV (red) outlines the eccentric esophageal wall thickening with PET-avid disease. The CTV (blue) includes the GTV with 1 cm radial expansion and 3-4 cm craniocaudal expansion (shown on a sagittal reconstruction inset). The PTV (green) adds 7 mm. Key organs at risk are labeled: bilateral lungs, heart, aorta, and spinal cord.</image>

<image>A comparison table of the major neoadjuvant and definitive treatment approaches for esophageal cancer. Columns: CROSS nCRT, FLOT perioperative chemotherapy, definitive CRT (RTOG 85-01). Rows include: indication, radiation dose, chemotherapy regimen, surgical approach, pCR rate, median OS, 5-year OS, and key advantages/disadvantages. The ESOPEC and NEO-AEGIS head-to-head trials are noted as ongoing or recently reported comparisons of CROSS vs. FLOT.</image>

Key Clinical Pearls

The CROSS trial remains the foundational study establishing neoadjuvant chemoradiation for esophageal cancer, demonstrating that 41.4 Gy combined with weekly carboplatin and paclitaxel followed by surgery significantly improves R0 resection rates and overall survival without increasing surgical morbidity. Radiation dose should not be escalated beyond 50.4 Gy in definitive chemoradiation, as the INT 0123 trial showed no survival benefit and increased toxicity at higher doses. SCC exhibits a substantially higher pathologic complete response rate to neoadjuvant chemoradiation than adenocarcinoma (49% versus 23% in CROSS), which has important implications for organ-preservation strategies in SCC. For GEJ adenocarcinoma, perioperative FLOT chemotherapy without radiation is a strong competing strategy; the ESOPEC trial suggests FLOT may be superior to CROSS for this subsite, underscoring the importance of multidisciplinary discussion. Finally, cardiac dose during esophageal radiation therapy is increasingly recognized as a critical factor; therefore, IMRT or VMAT techniques and deep inspiration breath hold (DIBH) for distal and GEJ tumors should be employed to minimize mean heart dose.

References

• van Hagen P et al. "Preoperative chemoradiotherapy for esophageal or junctional cancer." N Engl J Med. 2012;366(22):2074-2084.
• Shapiro J et al. "Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial." Lancet Oncol. 2015;16(9):1090-1098.
• Minsky BD et al. "INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy." J Clin Oncol. 2002;20(5):1167-1174.
• Al-Batran SE et al. "Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial." Lancet. 2019;393(10184):1948-1957.
• Herskovic A et al. "Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus." N Engl J Med. 1992;326(24):1593-1598.

Read this lecture as Markdown